Yesterday, Pharmaceutical company Strides Pharma Science shared the news that everyone wanted to hear for almost 2 months. According to the company’s latest production, there has been a formation of commercialized Favipiravir antiviral tablets to fight against the novel Coronavirus infection.
The company took procedural observations from the Toyoma Chemical company who produced Avigan and now has become the first Indian to produce a Coronavirus vaccine. Favipiravir was being studied by China and many strong economies such as the US, India, and the European Union.
Favipiravir is a complex derived generic version of Avigan, the drug used to treat influenza in Japan. As for now, the tests have been done in some cases.
After these trials were done, the company shared a small description of the results. “The drug has demonstrated positive outcomes, including a reduction in the duration of Covid-19 and improved lung conditions for the patients,” the company said.
As with the production, strategies about the medicinal distribution has also been shared by the firm. Currently, two dosages are being produced by the company. These are the 400 mg and the 200 mg strength tablets which are now being transported to Gulf countries, under their treatment program against the novel Coronavirus.
Strides have also urged the Indian administration panel to get on board with the new vaccine and make the drug available in the Indian market.
Also Read- Factors that could affect the production of the Vaccine
The continuous increase in fulfilling the need might bring an impact on the firm’s products soon. Strides have shared their ideas with potential API manufacturers and are expecting positive results.
As of today, the Bangalore facility of the company can produce up to 6 billion units of favipiravir tablets a year.
This high-performance facility has been approved by World Health Organization (WHO), US Food and Drug Administration (USFDA), Medicines and Healthcare products Regulatory Agency (MHRA), and Therapeutic Goods Administration (TGA).
Adding to this, the news of producing a COVID-19 vaccine became a wildfire on the stock market too. The company’s stock gained 20 percent and reached Rs 449.1 on the Bombay Stock Exchange (BSE).
Other prominent firms including Cipla, Glenmark, Zydus Cadila, and Dr. Reddy’s Laboratories are also working on the cure for the virus. Glenmark Pharmaceuticals has approached the Drug Controller General of India for testing their sample of Favipiravir on Coronavirus positive patients.
These drugs take a 14-days course period to act from scratch to permanently remove the virus from the lungs and the body. So it could take the time of around 30-days for the Indian citizens. Capital growth is to be provided and strict laws are to be applied for equal distribution.
Finally, as the rise in coronavirus vaccine increases, the market showed a positive response to the medicine budget and investment throughout the globe. According to some predictions, the global market for antiviral drugs could surpass the mark of $62.67 billion by the year 2022.